Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01928485
Other study ID # CASE6812
Secondary ID NCI-2013-01372
Status Terminated
Phase Phase 2
First received
Last updated
Start date August 30, 2013
Est. completion date November 7, 2016

Study information

Verified date September 2020
Source Case Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized phase II trial studies how well green tea extract works in treating patients with low-risk prostate cancer. Green tea extract contains ingredients that may prevent or slow the growth of certain cancers.


Description:

PRIMARY OBJECTIVES: I. To assess changes in the levels of total- and free- prostate-specific antigen (PSA), free to total PSA (f/tPSA) ratio and insulin-like growth factor 1 (IGF-I) levels and IGF-I/free PSA (fPSA) ratio, insulin-like growth factor binding protein 3 (IGFBP-3), and vascular endothelial growth factor (VEGF) after Sunphenon 90DCF-T (green tea extract) supplementation during the period between recruitment and biopsy. SECONDARY OBJECTIVES: I. To evaluate the effects of oral ingestion on Sunphenon 90DCF-T supplementation during the period between recruitment and biopsy in the reactivation of glutathione S-transferase pi 1 (GSTP1) (whole blood deoxyribonucleic acid [DNA]); levels of antigen identified by monoclonal antibody Ki-67 (Ki-67), cluster of differentiation 34 (CD34), and M30 apopotosense in the prostate tissue. II. To evaluate the effects of oral ingestion of Sunphenon 90DCF-T during the period between recruitment and biopsy on histologic findings in prostate tissue such as nuclear measurements viz. shape, size and texture and quality of life (QOL) assessment. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM A: Patients undergo active surveillance for 52 weeks. ARM B: Patients receive green tea extract orally (PO) once daily (QD) for 52 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days.


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date November 7, 2016
Est. primary completion date October 5, 2016
Accepts healthy volunteers No
Gender Male
Age group 45 Years to 85 Years
Eligibility Inclusion Criteria: - Patients must be males with histologically confirmed and clinically localized low-grade and low-volume prostate cancer demonstrated at the time of initial diagnosis - Prostate biopsy must be positive for cancer: clinically localized T1c or T2a, PSA = 10, Gleason = 6 at the time of initial diagnosis. As the intent of serial biopsy is to ensure that the disease has not progressed to the stage or grade of requiring treatment, the presence of a negative biopsy following an initial positive biopsy (coupled with clinically localized T1c or T2a PSA =10 and Gleason =6 for a patient who has had no treatment, will not render the patient ineligible. If the consecutive biopsy is either negative, or if positive and remains clinically localized T1c or T2a, PSA=10 and Gleason =6, the patient is eligible - Willing to refrain from the concurrent use of high-dose (200 mg or higher per day) of vitamins, antioxidants, Proscar, Advodart, and anti-inflammatory agents - Willing to sign an Institutional Review Board (IRB)-approved informed consent document and adhere to the protocol - Willing and able to take oral medications - Willing to refrain from drinking any kind of tea (including herbal tea) or using supplements containing green tea for the duration of the study - Subjects must have newly diagnosed (within 1 year), previously untreated prostate cancer without other malignancy; therefore, no prior therapies are permitted - Total bilirubin within normal institutional limits - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) = institutional upper limit of normal - Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) = institutional upper limit of normal - Serum creatinine within normal institutional limits - Subject must be willing to limit alcohol to moderate use which is defined as: up to one drink a day for women or two drinks a day for men; examples of one drink include: - Beer: 12 fluid ounces (355 milliliters) - Wine: 5 fluid ounces (148 milliliters) - Distilled spirits (80 proof): 1.5 fluid ounces (44 milliliters) Exclusion Criteria: - Patients who are receiving any other investigational agents - Patients with known concurrent malignancy - History of allergic reactions attributed to compounds of similar chemical or biologic composition to Sunphenon 90 DCF-T or other agents used in this study - Recent consumption of tea (six or more cups per day) or use of supplements containing green tea within one week of randomization; or concomitant use of at least 400 mg per day of a nonsteroidal anti-inflammatory (NSAID) agent two or more times per week - Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Patients who have received prior hormonal or surgical therapy for prostate cancer; including prior brachytherapy or radiation therapy - Signs or symptoms of progressive or uncontrolled liver disease - Known malignancy at any site within the last two years; with the exception of basal cell carcinoma (BCC) - Participation in a research trial within the past three months - Any condition that would interfere with the ability to give informed consent or comply with the study protocol - Hypersensitivity to tea products or any of the inactive ingredients found in the drug product capsules - Patients with a known history of Gilbert's syndrome

Study Design


Intervention

Other:
active surveillance
Undergo active surveillance
Drug:
Sunphenon
Given PO
Other:
laboratory biomarker analysis
Correlative studies
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
Sanjay Gupta PhD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total-PSA (tPSA) Levels tPSA serum levels From baseline at 52 weeks
Primary Changes in the f/tPSA Ratio The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated. From baseline at 52 weeks
Primary Changes in IGF-I Levels The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated. Baseline to 52 weeks
Primary Changes in the IGF-I/fPSA Ratio The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated. Baseline up to 52 weeks
Primary Changes in the Level of IGFBP-3 The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated. Baseline to 52 weeks
Primary Changes in the Level of VEGF The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated. Baseline up to 52 weeks
Primary Changes in the Levels of Free-PSA (f-PSA) The difference of serum biomarkers between two treatment arms will be compared using T-test or Kruskal-Wallis test if normality is violated. from baseline at 52 weeks
Secondary Effects of Oral Ingestion of Green Tea Extract in the Reactivation of GSTP1 (Whole Blood DNA) The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures analysis of variance (ANOVA). Up to 52 weeks
Secondary Effects of Oral Ingestion of Green Tea Extract on Levels of Ki-67 The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA. Up to 52 weeks
Secondary Effects of Oral Ingestion of Green Tea Extract on Levels of CD34 The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA. Up to 52 weeks
Secondary Effects of Oral Ingestion of Green Tea Extract on Levels of M30 Apoptosense in the Prostate Tissue The temporal pattern of biomarkers within same treatment group between baseline and subsequent time points will be analyzed using repeated measures ANOVA. Up to 52 weeks
Secondary Effects of Oral Ingestion of Sunphenon 90 DCF-T on Histologic Findings in Prostate Tissue Such as Nuclear Measurements Viz. Shape, Size and Texture Effects of oral ingestion of Sunphenon 90 DCF-T on histologic findings in prostate tissue such as nuclear measurements viz. shape, size and texture Up to 52 weeks
Secondary Quality of Life (QOL) Assessed by Mean Expanded Prostate Cancer Index Composite (EPIC-26) Scores Quality of Life (QOL) assessed by the Expanded Prostate Cancer Index Composite (EPIC-26). Scores for each domain (urinary incontinence, bowel, sexual, hormonal) range from 0-100, with higher scores indicating better clinical assessment. Baseline
Secondary Quality of Life (QOL) Assessed by Mean Expanded Prostate Cancer Index Composite (EPIC-26) Scores Quality of Life (QOL) assessed by the Expanded Prostate Cancer Index Composite (EPIC-26). Scores for each domain (urinary incontinence, bowel, sexual, hormonal) range from 0-100, with higher scores indicating better clinical assessment. At 24 weeks
Secondary Quality of Life (QOL) Assessed by Mean Expanded Prostate Cancer Index Composite (EPIC-26) Scores Quality of Life (QOL) assessed by the Expanded Prostate Cancer Index Composite (EPIC-26). Scores for each domain (urinary incontinence, bowel, sexual, hormonal) range from 0-100, with higher scores indicating better clinical assessment. at 3.5 years from start of study
Secondary Quality of Life (QOL) Assessed by Mean Medical Outcomes Study 12-item Short Form Health Survey (SF-12) Quality of Life (QOL) assessed by SF-12. The questionnaire consists of 12 items questioned weighted and summed to provide physical and mental health scores (PCS and MCS). The two composite scores are computed using the scores on twelve questions that range from 0 to 100, with higher score indicating better health. Baseline
Secondary Quality of Life (QOL) Assessed by Mean Medical Outcomes Study 12-item Short Form Health Survey (SF-12) Quality of Life (QOL) assessed by SF-12. The questionnaire consists of 12 items questioned weighted and summed to provide physical and mental health scores (PCS and MCS). The two composite scores are computed using the scores on twelve questions that range from 0 to 100, with higher score indicating better health. At 24 weeks
Secondary Quality of Life (QOL) Assessed by Mean Medical Outcomes Study 12-item Short Form Health Survey (SF-12) Quality of Life (QOL) assessed by SF-12. The questionnaire consists of 12 items questioned weighted and summed to provide physical and mental health scores (PCS and MCS). The two composite scores are computed using the scores on twelve questions that range from 0 to 100, with higher score indicating better health. At 3.5 years from start of study
Secondary Urinary Symptoms as Assessed by Mean American Urological Association Symptom Index (AUA) Urinary symptoms as assessed by American Urological Association Symptom Index (AUA). This is a 7-item symptom index measures frequency, nocturia, weakness of stream, hesitancy, intermittence, incomplete emptying and urgency. Scores range between 0 to 35, with higher scores indicating a worse clinical assessment. Baseline
Secondary Urinary Symptoms as Assessed by Mean American Urological Association Symptom Index (AUA) Urinary symptoms as assessed by American Urological Association Symptom Index (AUA). This is a 7-item symptom index measures frequency, nocturia, weakness of stream, hesitancy, intermittence, incomplete emptying and urgency. Scores range between 0 to 35, with higher scores indicating a worse clinical assessment. At 24 weeks
Secondary Urinary Symptoms as Assessed by Mean American Urological Association Symptom Index (AUA) Urinary symptoms as assessed by American Urological Association Symptom Index (AUA). This is a 7-item symptom index measures frequency, nocturia, weakness of stream, hesitancy, intermittence, incomplete emptying and urgency. Scores range between 0 to 35, with higher scores indicating a worse clinical assessment. At 3.5 years from start of study
Secondary Sexual Health Inventory in Men Score (SHIM Score) SHIM score - The SHIM score measures the severity of the participant's Erectile Dysfunction (ED) in points on a scale as follows:
22 - 25: No significant erectile dysfunction 17 - 21: Mild erectile dysfunction 12 - 16: Mild-to-moderate erectile dysfunction 8 - 11: Moderate erectile dysfunction 5 - 7: Severe erectile dysfunction
Reported values are an average of three collected data points per participant: at baseline, at 24 weeks, and at end of study (3.5 years)
Baseline, at 24 weeks, and at 3.5 years from start of study
See also
  Status Clinical Trial Phase
Completed NCT02217709 - Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer Phase 2
Completed NCT03233555 - Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer N/A
Completed NCT02846870 - Visually Enhanced Education About Prostate Cancer N/A
Completed NCT00103194 - Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer Phase 2
Completed NCT02250014 - The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer Phase 1
Terminated NCT01340599 - Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery Phase 2
Recruiting NCT04589468 - Researching the Effect of Exercise on Cancer N/A
Active, not recruiting NCT01823562 - Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery Phase 1
Active, not recruiting NCT01923506 - Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery Phase 1
Completed NCT01433913 - Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery Phase 2
Completed NCT00589472 - Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer Phase 2
Active, not recruiting NCT02176902 - Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer N/A
Completed NCT01117935 - Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer N/A
Completed NCT01656304 - Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy Phase 2
Recruiting NCT03880422 - Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors N/A
Terminated NCT01737151 - Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer N/A
Withdrawn NCT01859689 - Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer Phase 2
Withdrawn NCT01555632 - Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy N/A
Completed NCT00956163 - Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer Phase 0
Completed NCT00459407 - Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate Phase 1